MX381239B - Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). - Google Patents

Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).

Info

Publication number
MX381239B
MX381239B MX2017006567A MX2017006567A MX381239B MX 381239 B MX381239 B MX 381239B MX 2017006567 A MX2017006567 A MX 2017006567A MX 2017006567 A MX2017006567 A MX 2017006567A MX 381239 B MX381239 B MX 381239B
Authority
MX
Mexico
Prior art keywords
farnesoid
fxr
receptor
alpha
alkyl
Prior art date
Application number
MX2017006567A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006567A (es
Inventor
Alexander Weymouth-Wilson
Carl Otter
Ieuan Davies
James Boydell
Laura Wallis
Rob Clarkson
Zofia Komsta
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505675.7A external-priority patent/GB201505675D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006567A publication Critical patent/MX2017006567A/es
Publication of MX381239B publication Critical patent/MX381239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017006567A 2014-11-19 2015-11-19 Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr). MX381239B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505675.7A GB201505675D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053519 WO2016079520A1 (en) 2014-11-19 2015-11-19 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006567A MX2017006567A (es) 2018-01-26
MX381239B true MX381239B (es) 2025-03-12

Family

ID=54704022

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006567A MX381239B (es) 2014-11-19 2015-11-19 Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).

Country Status (10)

Country Link
US (2) US20170327531A1 (enExample)
EP (1) EP3221334B1 (enExample)
JP (1) JP6698085B2 (enExample)
KR (1) KR102527821B1 (enExample)
CN (1) CN107207558B (enExample)
CA (1) CA2968310A1 (enExample)
EA (1) EA033603B1 (enExample)
MX (1) MX381239B (enExample)
TW (1) TWI688571B (enExample)
WO (1) WO2016079520A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
PL3221333T3 (pl) 2014-11-19 2020-01-31 NZP UK Limited Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
EP3221332B1 (en) 2014-11-19 2019-04-24 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
WO2017111979A1 (en) * 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106046093A (zh) * 2016-05-30 2016-10-26 华东师范大学 一种石胆酸的合成方法
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN116178473B (zh) * 2018-12-10 2025-03-04 江西科睿药业有限公司 一种奥贝胆酸的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
AU2009276507B2 (en) * 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
JP5639073B2 (ja) 2008-11-19 2014-12-10 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５モジュレーターおよびその使用方法
CA2744189C (en) 2008-11-19 2016-10-11 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
SMT201700602T1 (it) 2012-10-26 2018-03-08 Intercept Pharmaceuticals Inc Processo per la preparazione di derivati dell’acido biliare
RU2693382C2 (ru) * 2012-11-28 2019-07-02 Интерсепт Фармасьютикалз, Инк. Лечение заболевания дыхательной системы
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
PT3360882T (pt) 2013-05-14 2021-02-12 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x
RU2015155590A (ru) 2013-05-24 2017-06-29 Нестек С.А. Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
JP6820253B2 (ja) 2014-05-29 2021-01-27 バール ファーマシューティカルズ ソチエタ レスポンサビリタ リミタータ Ｆｘｂ及びｔｇｒ５／ｇｐｂａｒ１介在性疾患の治療及び／又は予防に使用するためのコラン誘導体
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
PL3221333T3 (pl) 2014-11-19 2020-01-31 NZP UK Limited Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
EP3221332B1 (en) 2014-11-19 2019-04-24 NZP UK Limited 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
SG11201703997XA (en) 2014-11-26 2017-06-29 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
AU2016280806B2 (en) 2015-06-19 2021-01-28 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
US20170327531A1 (en) 2017-11-16
EA033603B1 (ru) 2019-11-08
CN107207558B (zh) 2019-10-29
US20190077827A1 (en) 2019-03-14
JP2017534669A (ja) 2017-11-24
MX2017006567A (es) 2018-01-26
WO2016079520A1 (en) 2016-05-26
EP3221334A1 (en) 2017-09-27
KR102527821B1 (ko) 2023-05-02
EA201790885A1 (ru) 2017-11-30
HK1244286A1 (en) 2018-08-03
JP6698085B2 (ja) 2020-05-27
KR20170099896A (ko) 2017-09-01
CA2968310A1 (en) 2016-05-26
TW201632539A (zh) 2016-09-16
TWI688571B (zh) 2020-03-21
CN107207558A (zh) 2017-09-26
US10597423B2 (en) 2020-03-24
EP3221334B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
MX381239B (es) Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
MX375863B (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX375865B (es) Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).
MX375864B (es) Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
MX2020004024A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY34472A (es) Derivados modificados de 4-fenil-piridina
MX2017002013A (es) Polimorfos de selinexor.
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CR20180426A (es) Profarmacos del moculador selectivo del receptor de la progesterona (msrp) (11.beta., 17.beta)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona
UY34457A (es) Composición de Nitazoxanida mejorada y proceso para prepararla
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.
IN2014MU00171A (enExample)